(NYSE: HLN) Haleon's forecast annual revenue growth rate of 3.77% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.67%.
Haleon's revenue in 2025 is $14,588,311,688.On average, 4 Wall Street analysts forecast HLN's revenue for 2025 to be $135,050,251,262,401, with the lowest HLN revenue forecast at $131,946,478,371,767, and the highest HLN revenue forecast at $136,337,460,643,753. On average, 3 Wall Street analysts forecast HLN's revenue for 2026 to be $141,878,170,105,306, with the lowest HLN revenue forecast at $141,576,590,404,795, and the highest HLN revenue forecast at $142,189,923,578,846.
In 2027, HLN is forecast to generate $147,926,986,859,864 in revenue, with the lowest revenue forecast at $147,246,742,960,694 and the highest revenue forecast at $148,848,476,351,991.